<DOC>
	<DOCNO>NCT00649090</DOCNO>
	<brief_summary>The purpose study give access postmenopausal woman estrogen sensitive primary breast cancer exemestane adjuvant treatment breast cancer use tamoxifen collect serious adverse event .</brief_summary>
	<brief_title>A Study Evaluate Safety Adjuvant Treatment With Exemestane Following Previous Treatment With Tamoxifen Postmenopausal Women With Estrogen Sensitive Primary Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Postmenopausal patient Patients early breast cancer adequate locoregional treatment eventual adjuvant chemotherapy , treat tamoxifen 23 year OR treat tamoxifen 23 year consecutive exemestane treatment , provide total duration endocrine treatment le 5 year Estrogen receptor positive breast cancer patient Patients remain free disease follow treatment tamoxifen Patients take drug adjuvant treatment breast cancer Patients take hormone replacement therapy Donation blood blood product transfusion 30 day prior initiation treatment study drug , time program 30 day completion treatment</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
</DOC>